CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Leap Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Leap Therapeutics Inc
47 Thorndike St Ste B1-1
Phone: (617) 252-4343p:617 252-4343 CAMBRIDGE, MA  02141-1799  United States Ticker: LPTXLPTX
Business Summary
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Christopher K.Mirabelli 68 4/1/2020 1/1/2011
President, Chief Executive Officer, Director Douglas E.Onsi 54 4/1/2020 1/1/2011
Chief Operating Officer Augustine J.Lawlor 66 1/1/2016 1/1/2016
9 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Macrocure Ltd. Kiryat Matalon, 25, Ha-Sivim Petach Tikva Israel
Flame Biosciences, Inc. 555 Madison Avenue New York City NY United States

Business Names
Business Name
Flame Biosciences LLC
GITR, Inc.
HealthCare Pharmaceuticals Pty Ltd.
Leap Securities Corp.
LPTX
Macrocure Ltd

General Information
Number of Employees: 54 (As of 12/31/2023)
Outstanding Shares: 38,261,130 (As of 4/15/2024)
Shareholders: 74
Stock Exchange: NASD
Federal Tax Id: 274412575
Fax Number: (302) 636-5454
Email Address: info@leaptx.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024